Scientists at Tyumen State University have discovered a new natural compound that promises to be a revolutionary antibiotic. It is reported to be able to inhibit drug resistance in bacteria.
Hunting for the "wolves of the microbial world"
In studies, the most pronounced effect was demonstrated against gram-positive bacteria. Such bacteria include the famous "wolves of the microbial world": staphylococci, streptococci and many other dangerous bacteria. The drug also has antifungal and antitumor activity (there are many antibiotics that treat tumors).
Such a drug is definitely needed. Will the glory of penicillin wait for him? Like the first antibiotic, it was also discovered in microscopic fungi with the complex name Emericellopsis alkalina. From them, the antibiotic got its complex name: emericillipsin A.
Three directions of impact
An article about this antibiotic was published in the latest issue of the international scientific medical journal “Applied Biochemistry and Microbiology”. The first publication about it appeared two years ago in the scientific journal "Molecules", and even then its activity was described against the fungi Candida and Aspegillus, many bacteria and a number of tumor cells. “The molecular mechanism of action of emericillipsin A is most likely associated with its effect on cell membranes,” the authors of the article noted. "Emericillipsin A is a fairly short peptaibol that may be useful for the development of antifungal, antibacterial, or anticancer agents." The study of the future antibiotic is being carried out by a large group of scientists from the Tyumen State University, the N.N. GF Gauze and a number of other metropolitan scientific institutions.
We asked the host to comment on the news about a promising drug antibiotic specialist in Russia Roman Kozlova, he is a corresponding member of the Russian Academy of Sciences, chief freelance specialist of the Ministry of Health of Russia on clinical microbiology and antimicrobial resistance, head of the WHO Collaborating Center for Capacity Building in the Surveillance of Antimicrobial Resistance Studies:
- Such studies are needed, they are promising. But you need to clearly understand that the path from the compound, no matter whether it is natural, as in this case, or synthetic, to the finished drug is a long process. It is not yet clear what the dosage form will be: pills, injections, or something else. It is unclear whether this substance will be as effective in patients as it is now shown to be experimentally. It is especially important that it is safe for humans. All of this should be studied in solid evidence-based clinical trials.
The same applies to other antibiotics that are now being actively studied in Russia. Some are in the same stage as emericillipsin A, others are in earlier or later stages.
But the problem of antibiotic resistance is so acute that new antibiotics are needed right now. In recent years, about 15 such fundamentally new drugs have been created in the world, but unfortunately, not all of them are registered in our country. Many of them would be very useful in Russia today. Why are they not registered? The problem is primarily in the price. These drugs cannot be cheap because their development and testing are very expensive. This is the reality of modern pharmacology.
On the other hand, their treatment should not be as broad as it is with antibiotics today. They need to be prescribed more specifically, after a clear definition of the specific microorganism that caused the disease. This requires high quality microbiological diagnostics. Is there a way out of this situation? I think the treatment model with modern antibiotics should be changed. In fact, treating serious infections with such drugs should be about the same as treating cancer. This should also be targeted (targeted) therapy based on modern high-quality microbiological diagnostics. This allows us to prescribe a precisely effective antibiotic against the specific microorganism that caused the disease. You need to understand that the development of bacterial resistance to antibiotics is an inevitable process, this is due to nature. But this is the only way we can minimize the development of antibiotic resistance. There is no other way.